Navigation Links
Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
Date:9/20/2010

BURLINGAME, Calif., Sept. 20 /PRNewswire/ -- Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties. Under a special arrangement the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts. The antibodies will be available to Parkinson's researchers in academic/nonprofit and industry labs on a worldwide basis.

"After a successful project to develop these LRRK2 antibodies, we are very pleased that MJFF has also chosen Epitomics to now distribute these important antibodies to the research community going forward," said Guo-Liang Yu, CEO of Epitomics. "We are happy to support this important area of research and lend a hand in helping researchers develop LRRK2 based therapies."  

"LRRK2 antibodies are critical to help move Parkinson's research forward," said Mark Frasier, PhD, associate director of research programs at MJFF. "The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers. Epitomics has been a great partner and we are excited that they will continue to help MJFF remove barriers to developing Parkinson's therapies."

How to Obtain LRRK2 Antibodies

These antibodies can be ordered directly from Epitomics. Detailed product information can be found on Epitomics Web site at www.epitomics.com.

About LRRK2 and LRRK2 Antibodies

LRRK2 is a Parkinson's-implicated gene discovered in 2004 that is now believed to be the single greatest genetic contributor to the disease. While it is the focus of intensive research in the Parkinson's field, a major roadblock to the successful development of LRRK2-based therapies has been the lack of high-quality LRRK2 antibodies. Antibodies are used by researchers to identify where proteins can be found in the body, how they behave in cells and how to manipulate their activity. In 2009 MJFF engaged Epitomics to generate several highly sensitive and specific LRRK2 antibodies in large amounts.

Further scientific information and discussion on the LRRK2 antibodies can be found at the PD Online Research Web site at www.pdonlineresearch.org.

About Epitomics, Inc.

Epitomics, Inc is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The Company's core technology is its unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.  

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded almost $196 million in research to date.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
2. Metamark Genetics, Inc. Announces New Chief Scientific Officer
3. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
4. Dendreon Announces Change in Board of Directors
5. Executive Mindshare Announces New Social Media Platform for Vertical Business Networks
6. DSM Biomedical Announces Continued Partnership with Spinelab
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Stemedica Announces Completion of Clinical Stem Cell Master Bank
9. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
10. RRD Announces Move to New Corporate Headquarters
11. Huifeng Bio-Pharmaceutical Technology, Inc. Announces the Acquisition of Shangqiu Kexin Rutin Processing Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):